The authors demonstrated that Neo2/15 treatment expanded cytotoxic CD8+ T cells over T regulatory cells, and the combination therapy with Neo2/15 and a tumor-targeting monoclonal antibody significantly improved the tumor growth inhibition in a murine melanoma model. Here, CD8A is linked to neoplasm.